Sola Failure Decreases Value of Biogen's (BIIB) Aducanumab - BMO Capital

November 23, 2016 9:27 AM EST
Get Alerts BIIB Hot Sheet
Price: $287.77 -0.61%

Rating Summary:
    18 Buy, 15 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade BIIB Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

BMO Capital analyst M. Ian Somaiya weighed in on Biogen (NASDAQ: BIIB) with shares down on Eli Lilly's solanezumab's failure. The analyst said the news decreases the value of aducanumab's.

Somaiya commented, "We expect BIIB shares to trade down on solanezumab's failureā€Ž, as we believe another Abeta drug failure increases aducanumab's development risk. But downside likely limited (10-15% in our view) given aducanumab's better Abeta oligomer targeting and trial design (early vs. sola's mild patients). We believe positive titration data (CTAD, 12/9), supporting safe use of highest, most effective dose from P1b, are key to aducanumab's P3 success or at a minimum realizing value in an M&A."

The firm maintained an Market Perform rating and price target of $294.00

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $318.11 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA, Trader Talk

Related Entities

BMO Capital

Add Your Comment